Bank of America
KROS icon

Bank of America’s Keros Therapeutics KROS Stock Holding History

Bank of America’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$592K Sell
53,654
-46,460
-46% -$717K ﹤0.01% 4808
2025
Q4 		$2.04M Sell
100,114
-126,013
-56% -$2.21M ﹤0.01% 4056
2025
Q3 		$3.58M Sell
226,127
-69,350
-23% -$1.02M ﹤0.01% 4328
2025
Q2 		$3.94M Buy
295,477
+139,865
+90% +$1.89M ﹤0.01% 4136
2025
Q1 		$1.59M Sell
155,612
-5,855
-4% -$68K ﹤0.01% 4872
2024
Q4 		$2.56M Sell
161,467
-9,604
-6% -$499K ﹤0.01% 4232
2024
Q3 		$9.93M Sell
171,071
-7,923
-4% -$391K ﹤0.01% 3071
2024
Q2 		$8.18M Buy
178,994
+6,517
+4% +$350K ﹤0.01% 3154
2024
Q1 		$11.4M Sell
172,477
-20,972
-11% -$1.24M ﹤0.01% 2870
2023
Q4 		$7.69M Buy
193,449
+138,799
+254% +$4.35M ﹤0.01% 3164
2023
Q3 		$1.74M Sell
54,650
-1,563
-3% -$58.4K ﹤0.01% 4385
2023
Q2 		$2.26M Sell
56,213
-19,456
-26% -$853K ﹤0.01% 4115
2023
Q1 		$3.23M Buy
75,669
+9,728
+15% +$491K ﹤0.01% 3943
2022
Q4 		$3.17M Buy
65,941
+12,831
+24% +$599K ﹤0.01% 3829
2022
Q3 		$2M Buy
53,110
+14,341
+37% +$497K ﹤0.01% 4275
2022
Q2 		$1.07M Buy
38,769
+4,480
+13% +$197K ﹤0.01% 4851
2022
Q1 		$1.86M Buy
34,289
+2,926
+9% +$150K ﹤0.01% 4661
2021
Q4 		$1.83M Buy
31,363
+1,216
+4% +$60.6K ﹤0.01% 4647
2021
Q3 		$1.19M Buy
30,147
+22,154
+277% +$788K ﹤0.01% 4909
2021
Q2 		$339K Sell
7,993
-6,494
-45% -$352K ﹤0.01% 5715
2021
Q1 		$892K Buy
14,487
+12,388
+590% +$785K ﹤0.01% 4931
2020
Q4 		$148K Buy
2,099
+1,121
+115% +$70.6K ﹤0.01% 5781
2020
Q3 		$38K Sell
978
-8,385
-90% -$333K ﹤0.01% 6107
2020
Q2 		$351K Buy
+9,363
New +$288K ﹤0.01% 4875

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Bank of America's KROS Position: Q1 2026 in Review

Bank of America reduced its Keros Therapeutics (KROS) stake by 46% in Q1 2026, selling an estimated $717K and leaving 53,654 shares worth $592K. The position accounts for ﹤0.01% of the portfolio, ranked #4808.

Bank of America first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $11.4M in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Bank of America held 53,654 shares of Keros Therapeutics worth $592K as of Q1 2026.
  • Bank of America sold 46,460 Keros Therapeutics shares in Q1 2026, an estimated $717K.
  • Keros Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4808 holding.
  • Bank of America first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Bank of America's Keros Therapeutics position peaked at $11.4M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.